Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 2/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.33 |
| ▸ | ALOX5 | P09917 | 3/20 | 0.33 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.32 |
| ▸ | AHR | P35869 | 3/20 | 0.31 |
| ▸ | ERBB2 | P04626 | 1/20 | 0.31 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.31 |
| ▸ | FYN | P06241 | 1/20 | 0.31 |
| ▸ | MAOA | P21397 | 1/20 | 0.31 |
| ▸ | ACHE | P22303 | 1/20 | 0.31 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18101711 | 0.91 | CYP1A2 (0.36) | MEN1KMT2AALOX5TDP1AHR | |
| SCHEMBL21940432 | 0.90 | ALOX5 (0.35) | MEN1KMT2AALOX5TDP1AHR | |
| SCHEMBL18798585 | 0.89 | CYP1A2 (0.34) | MEN1KMT2AALOX5TDP1AHR | |
| SCHEMBL18101505 | 0.89 | KDM4E (0.33) | MEN1KMT2AALOX5MAOA | |
| SCHEMBL19157045 | 0.88 | — | — | |
| SCHEMBL18101703 | 0.88 | ALOX5 (0.34) | MEN1KMT2AALOX5AHRL3MBTL1 | |
| SCHEMBL18101545 | 0.88 | MEN1 (0.35) | MEN1KMT2ATDP1CYP1A2 | |
| SCHEMBL18101577 | 0.86 | ALOX5 (0.30) | MEN1KMT2AALOX5 | |
| SCHEMBL18101692 | 0.86 | KDM4E (0.32) | MEN1KMT2AALOX5TDP1L3MBTL1 | |
| SCHEMBL18101526 | 0.86 | TNKS (0.32) | ALOX5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3196198-A1 | NOVEL COMPOUND AND ORGANIC ELECTROLUMINESCENCE ELEMENT USING SAME | Idemitsu Kosan Co., Ltd (JP) | 2017-07-26 | — | — | EP | disclosed |
| US-20160284998-A1 | NOVEL COMPOUND AND ORGANIC ELECTROLUMINESCENCE DEVICE OBTAINED BY USING SAME | IDEMITSU KOSAN CO., LTD. (JP) | 2016-09-29 | — | — | US | disclosed |
| US-20160284998-A1 | NOVEL COMPOUND AND ORGANIC ELECTROLUMINESCENCE DEVICE OBTAINED BY USING SAME | IDEMITSU KOSAN CO., LTD. (JP) | 2016-09-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160284998-A1 | NOVEL COMPOUND AND ORGANIC ELECTROLUMINESCENCE DEVICE OBTAINED BY USING SAME | EPB41, RPS4X, OR10J3 | MEN1 1397/4885KMT2A 2273/4885ALOX5 2749/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.